Small Molecule · SPT-320

GlyphAgo (SPT-320)

Phase 2Seaport Therapeutics (SPTX)

Oral, 'Glyphed' prodrug of agomelatine (an MT1/MT2 melatonin receptor agonist and serotonin 5-HT2C receptor antagonist) developed by Seaport Therapeutics on its Glyph platform for generalized anxiety disorder. The prodrug is designed to be absorbed through the intestinal lymphatic system rather than the portal vein, bypassing the first-pass liver metabolism that removes over 90% of unmodified agomelatine, so that effective agomelatine exposures can be reached at a lower dose with less liver exposure. The aim is to reduce or eliminate the dose-dependent liver-enzyme elevations and routine liver-function testing that have limited agomelatine, which is approved for GAD in Australia and for MDD in Australia and the EU but not in the US. In a Phase 1 trial in healthy volunteers it gave a 6.8-fold increase in agomelatine bioavailability and 10-fold lower pharmacokinetic variability than unmodified agomelatine, with no food or oral-contraceptive effect and no liver-related adverse events; a Phase 2a trial in GAD with sleep disturbance began in October 2026.

Also known as: SPT-320, SPT 320, GlyphAgo, Glyph Agomelatine, GlyphAgomelatine

Key facts

Modality
Small molecule
Chemistry
Prodrug
Mechanism
MT1 agonist
Highest phase
Phase 2
Developer
Seaport Therapeutics (SPTX)
Trials
2 tracked · 1 recruiting
Next catalyst
Early 2028 — Topline data (Generalized anxiety disorder)

Mechanism of action#

SPT-320 is a prodrug; its pharmacology is that of the released parent, agomelatine, a melatonin MT1/MT2 receptor agonist and serotonin 5-HT2C receptor antagonist that is an approved anxiolytic and antidepressant outside the US. The Glyph modification moves absorption to the gut lymphatics (in preclinical work over 50% of agomelatine was transported through the mesenteric lymphatics) to avoid first-pass liver metabolism and lower liver exposure.

TargetActionAffinity
MT1primaryMTNR1AAgonist—ⓘ
5-HT2CHTR2CAntagonist—ⓘ
MT2MTNR1BAgonist—ⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
GlyphAgo (SPT-320) oral, once dailyGlyph lymphatic-absorption prodrug
Phase 2a: 16 mg/day (about 5 mg agomelatine) or 32 mg/day (about 10 mg agomelatine) for six weeks. Phase 1: single ascending doses containing 2.5, 5 and 10 mg agomelatine equivalents, a food-effect/oral-contraceptive crossover against agomelatine 25 mg, and seven-day once-daily multiple ascending doses including 16 mg and 32 mg.
OralOnce daily—

Development timeline#

Jan 26Jul 26Jan 27Jul 27Jan 28Jul 28TodayPhase 18 Jun 2026 — readout (met) — Phase 1 MAD topline: seven-day dosing of GlyphAgo reached therapeutic agomelatine exposures at doses projected to avoid liver enzyme elevations; dose-dependent AUC and Cmax; no serious or liver-related adverse events.8 Jun 2026 — Phase 1 Results — Positive Phase 1 multiple-ascending dose results for GlyphAgo2 Apr 2026 — readout (met) — Phase 1 SAD and crossover topline: GlyphAgo gave a 6.8-fold increase in agomelatine bioavailability (90% CI 4.7-10.0) and 10-fold lower PK variability vs unmodified agomelatine, exceeding the 2-fold target; 9.6-14.5-fold higher dose-normalized exposure in SAD; no liver-related adverse events.2 Apr 2026 — Phase 1 Results — Positive Phase 1 SAD and crossover results for GlyphAgo11 Sept 2025 — phase change — Seaport announced dosing of the first participant in the multipart Phase 1 trial of GlyphAgo in healthy adult volunteers (SAD, MAD and food-effect crossover; open-label and placebo-controlled). Announcement date used; the true first dose is on or before it.11 Sept 2025 — Trial started — First participant dosed in Phase 1 trial of GlyphAgo (SPT-320)Phase 231 Dec 2028 — upcoming — Topline from the planned global, randomized, placebo-controlled Phase 2/3 trial of GlyphAgo in GAD (start planned 1H 2027), expected by year-end 2028.31 Mar 2028 — upcoming — Topline from the Phase 2a proof-of-pharmacology trial of GlyphAgo in GAD with sleep disturbance (sleep by ISI and EEG; HAM-A, CGI-S), expected early 2028.11 Oct 2026 — Conference presentation — GlyphAgo Phase 1 pharmacokinetic data presented at ECNP 20267 Oct 2026 — phase change — First patient dosed in the six-week, randomized, double-blind Phase 2a trial in adults with GAD and sleep disturbance in Australia (16 or 32 mg/day). Announcement date used.7 Oct 2026 — Trial started — First patient dosed in Phase 2a trial of GlyphAgo in GAD with sleep disturbance
Phase change Readout Event UpcomingHover a marker for details.
Phase 2Oct 2026 – Dec 2028
  1. UpcomingTopline from the planned global, randomized, placebo-controlled Phase 2/3 trial of GlyphAgo in GAD (start planned 1H 2027), expected by year-end 2028.↗
  2. UpcomingTopline from the Phase 2a proof-of-pharmacology trial of GlyphAgo in GAD with sleep disturbance (sleep by ISI and EEG; HAM-A, CGI-S), expected early 2028.↗
  3. Conference presentationGlyphAgo Phase 1 pharmacokinetic data presented at ECNP 2026↗
  4. First patient dosed in the six-week, randomized, double-blind Phase 2a trial in adults with GAD and sleep disturbance in Australia (16 or 32 mg/day). Announcement date used.↗
  5. Trial startedFirst patient dosed in Phase 2a trial of GlyphAgo in GAD with sleep disturbance↗
Phase 1Sept 2025 – Jun 2026
  1. metPhase 1 MAD topline: seven-day dosing of GlyphAgo reached therapeutic agomelatine exposures at doses projected to avoid liver enzyme elevations; dose-dependent AUC and Cmax; no serious or liver-related adverse events.↗
  2. Phase 1 ResultsPositive Phase 1 multiple-ascending dose results for GlyphAgo↗
  3. metPhase 1 SAD and crossover topline: GlyphAgo gave a 6.8-fold increase in agomelatine bioavailability (90% CI 4.7-10.0) and 10-fold lower PK variability vs unmodified agomelatine, exceeding the 2-fold target; 9.6-14.5-fold higher dose-normalized exposure in SAD; no liver-related adverse events.↗
  4. Phase 1 ResultsPositive Phase 1 SAD and crossover results for GlyphAgo↗
  5. Seaport announced dosing of the first participant in the multipart Phase 1 trial of GlyphAgo in healthy adult volunteers (SAD, MAD and food-effect crossover; open-label and placebo-controlled). Announcement date used; the true first dose is on or before it.↗
  6. Trial startedFirst participant dosed in Phase 1 trial of GlyphAgo (SPT-320)↗

GlyphAgo (SPT-320) for Generalized anxiety disorder#

Phase 2RecruitingGeneralized anxiety disorder indication →

GlyphAgo (SPT-320), an oral lymphatic-absorption prodrug of agomelatine, for generalized anxiety disorder (GAD), Seaport Therapeutics' second clinical program. A multipart Phase 1 trial in about 174 healthy volunteers in Australia (SAD, food-effect/oral-contraceptive crossover and seven-day MAD; protocol SPT-320-2024-101) began in September 2025 and completed in 2026: GlyphAgo raised agomelatine bioavailability 6.8-fold over unmodified agomelatine (above the program's 2-fold target), cut PK variability 10-fold, showed no food or oral-contraceptive effect, and produced no serious, severe or liver-related adverse events and no clinically significant changes in ALT, AST or bilirubin. On 2026-10-07 Seaport dosed the first patient in a six-week, randomized, double-blind Phase 2a proof-of-pharmacology trial in Australia in adults with GAD and sleep disturbance (16 or 32 mg/day; sleep endpoints by Insomnia Severity Index and EEG sleep architecture, plus HAM-A and CGI-S), with topline expected in early 2028. A global, randomized, placebo-controlled Phase 2/3 trial in GAD (earlier described as a potentially registration-enabling Phase 2b) is planned to start in 1H 2027 with topline by year-end 2028. No regulatory designations disclosed.

Readouts

  • By year-end 2028AnticipatedTopline data

    Topline from the planned global, randomized, placebo-controlled Phase 2/3 trial of GlyphAgo in GAD (start planned 1H 2027), expected by year-end 2028. ↗

  • Early 2028AnticipatedTopline data

    Topline from the Phase 2a proof-of-pharmacology trial of GlyphAgo in GAD with sleep disturbance (sleep by ISI and EEG; HAM-A, CGI-S), expected early 2028. ↗

  • 2026-06-08ReportedTopline datamet

    Phase 1 MAD topline: seven-day dosing of GlyphAgo reached therapeutic agomelatine exposures at doses projected to avoid liver enzyme elevations; dose-dependent AUC and Cmax; no serious or liver-related adverse events. ↗

  • 2026-04-02ReportedTopline datamet

    Phase 1 SAD and crossover topline: GlyphAgo gave a 6.8-fold increase in agomelatine bioavailability (90% CI 4.7-10.0) and 10-fold lower PK variability vs unmodified agomelatine, exceeding the 2-fold target; 9.6-14.5-fold higher dose-normalized exposure in SAD; no liver-related adverse events. ↗

Clinical trials#

Phase 2Recruiting

Phase 2a randomized, double-blind proof-of-pharmacology trial of GlyphAgo (SPT-320) in adults with generalized anxiety disorder and sleep disturbance - Australia

Started Oct 2026

SPT-320-2024-101Phase 1Completedn=174

Multipart Phase 1 proof-of-concept trial of GlyphAgo (SPT-320) in healthy volunteers (SAD, food-effect/oral-contraceptive crossover vs agomelatine, MAD) - Australia

Started Sept 2025

Conference coverage#

SPT-320 appears in 1 CNS Pulse conference abstract:

Sources#

  1. Bonner D, et al. GlyphAgo demonstrated 6.8-fold bioavailability and 10-fold reduced variability versus unmodified agomelatine (ECNP 2026, PS02-2029) — CNS Pulse (ECNP 2026 abstract)
  2. First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance (2026-10-07) — Psychiatric Times
  3. GlyphAgo for Treatment of Anxiety Shows Positive Phase 1 Topline Results (2026-04-02) — Psychiatric Times
  4. Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo (SPT-320) in Healthy Volunteers (2025-09-11) — Seaport Therapeutics
  5. Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers (2026-06-08, Business Wire copy) — Seaport Therapeutics (via BioSpace)